title: Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses.
abstract: Transgenic mice lacking an intact beta 2-microglobulin (beta 2m) gene fail to express major histocompatibility complex (MHC) class I proteins on the cell surface and, as a result, are virtually devoid of CD4- CD8+ lymphocytes. These animals provide a unique model system for directly assessing the role of CD8+ lymphocytes in the modulation of viral infection in vivo. beta 2m- CD8- mice and their normal littermates were inoculated at the base of the tail with the WR strain of vaccinia virus and monitored for serum antibody and lesion formation. Both groups developed similar lesions in response to a broad virus dose range, and all animals had completely recovered by day 28 after inoculation. Isotype-specific immunoglobulin levels were determined for each animal on day 7 and day 14 after primary inoculation, and again 7 days after a virus challenge. The virus-specific IgG1, IgG2a, and IgG2b levels were significantly different in the beta 2m-/- group (20-, 9-, and 30-fold lower, respectively, on day 7 after challenge) compared with the beta 2m+/- group. Virus-specific serum IgM levels for both groups remained similar throughout the experiment. In a separate experiment, beta 2m-/- mice were immunized with a nonviral antigen, 2,4,6-trinitrophenyl-conjugated keyhole limpet hemocyanin, and both total and antigen-specific isotype-specific immunoglobulin titers were determined. Total IgG1, IgG2a, IgG2b, and IgG3 tended to be lower overall in the beta 2m-/- mice compared with beta 2m+/- littermates. In contrast, total and antigen-specific IgE titers were similar in the two groups. These data indicate that CD8+ lymphocytes are not required to clear high doses of vaccinia virus, and they suggest that beta 2m-/- mice are less efficient at antigen-specific IgG production than their beta 2m+/- littermates.
authors.affiliation: Department of Molecular Biology, Immunex Research and Development Corporation, Seattle, WA 98101.
authors.forename: M K
authors.initials: MK
authors.lastname: Spriggs
authors.forename: B H
authors.initials: BH
authors.lastname: Koller
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: P J
authors.initials: PJ
authors.lastname: Morrissey
authors.forename: W C
authors.initials: WC
authors.lastname: Fanslow
authors.forename: O
authors.initials: O
authors.lastname: Smithies
authors.forename: R F
authors.initials: RF
authors.lastname: Voice
authors.forename: M B
authors.initials: MB
authors.lastname: Widmer
authors.forename: C R
authors.initials: CR
authors.lastname: Maliszewski
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000917:Antibody Formation; D016827:CD8 Antigens / Q000378:metabolism*; D005434:Flow Cytometry; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D008198:Lymph Nodes / Q000166:cytology; D051379:Mice; D008822:Mice, Transgenic; D013154:Spleen / Q000166:cytology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014301:Trinitrobenzenes / Q000276:immunology; D014615:Vaccinia / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology; D001613:beta 2-Microglobulin / Q000172:deficiency*
chemical_list: D000914:Antibodies, Viral; D016827:CD8 Antigens; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014301:Trinitrobenzenes; D001613:beta 2-Microglobulin; D007073:Immunoglobulin E